Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer per Antonio Gonçalves, Mathilde Marchand, Phyllis Chan, Jin Y. Jin, Jérémie Guedj, René Bruno

Obtenir text complet

Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches per Mathilde Marchand, Antonio Gonçalves, François Mercier, Pascal Chanu, Jin Y. Jin, Jérémie Guedj, René Bruno

Obtenir text complet

Does climate help modeling COVID-19 risk and to what extent? per Giovanni Scabbia, Antonio Sanfilippo, Annamaria Mazzoni, Dunia Bachour, Daniel Perez-Astudillo, Veronica Bermudez, Etienne Wey, Mathilde Marchand-Lasserre, Laurent Saboret

Obtenir text complet

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework per Phyllis Chan, Mathilde Marchand, Kenta Yoshida, Shweta Vadhavkar, Nina Wang, Alyse Lin, Benjamin Wu, Marcus Ballinger, Nitzan Sternheim, Jin Y. Jin, René Bruno

Obtenir text complet

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma per Brendan Bender, Chi‐Chung Li, Mathilde Marchand, David C. Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu

Obtenir text complet